Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus b conjugate vaccine (Boryung)
- Development stage
- Unknown
- Lead developer
- Boryung Biopharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Euhib is a monovalent conjugate vaccine developed by Boryung Biopharma for the prevention of invasive infections caused by Haemophilus influenzae type b (Hib), such as meningitis and pneumonia, in infants and children. The vaccine consists of the purified capsular polysaccharide polyribosylribitol phosphate (PRP) of Hib covalently bound to a tetanus toxoid carrier protein. This conjugation enhances the immune response by engaging T-cells, leading to higher antibody titers and the development of immunological memory in young children who typically respond poorly to pure polysaccharide antigens. It is administered via intramuscular injection and is approved for pediatric immunization schedules.
- Brand names
- Euhib
- Other names
- haemophilus influenzae type b vaccinePRP-T vaccineEuhib Inj
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on haemophilus b conjugate vaccine (Boryung).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus b conjugate vaccine (Boryung).